Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.48 |
| ▸ | PPARA | Q07869 | 5/20 | 0.48 |
| ▸ | CTSK | P43235 | 7/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 4/20 | 0.46 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15448116 | 0.89 | PPARA (0.57) | CTSSPPARACTSKCTSBCTSL | |
| SCHEMBL17291652 | 0.89 | PPARA (0.57) | CTSSPPARACTSKCTSBCTSL | |
| SCHEMBL20974785 | 0.89 | PPARA (0.57) | CTSSPPARACTSKCTSBCTSL | |
| SCHEMBL31385360 | 0.87 | CTSS (0.48) | CTSSPPARACTSKCTSBCTSL | |
| SCHEMBL25361007 | 0.87 | KLK5 (0.47) | CTSSPPARACTSKCTSBCTSL | |
| SCHEMBL31385404 | 0.87 | PPARA (0.46) | CTSSPPARACTSKCTSBCTSL | |
| SCHEMBL3753366 | 0.87 | KLK5 (0.47) | CTSSPPARACTSKCTSBCTSL | |
| SCHEMBL3753362 | 0.87 | KLK5 (0.47) | CTSSPPARACTSKCTSBCTSL | |
| SCHEMBL31385263 | 0.86 | PPARA (0.46) | CTSSPPARACTSKCTSBCTSL | |
| SCHEMBL28684646 | 0.85 | CYP1A2 (0.46) | CTSSPPARACTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065445-B2 | CDK2 inhibitors and methods of using the same | CEDILLA THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240174680-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4284365-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230109076-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2022165513-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174680-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | CTSS 2818/4885PPARA 3679/4885CTSK 2237/4885 |
| US-20230109076-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | CTSS 2818/4885PPARA 3679/4885CTSK 2237/4885 |
| US-12065445-B2 | CDK2 inhibitors and methods of using the same | CDK2, CDK20, CDK1 | CTSS 3268/4885PPARA 3800/4885CTSK 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.